Stem Cell Therapy vs. Gene Therapy: A 2026 Guide to Genetic Healing
In the world of advanced medicine, “stem cell therapy” and “gene therapy” are often mentioned together. While both represent the cutting edge of treatment, they are not the same. Understanding the fundamental difference between these two approaches is key to knowing which conditions they can treat. Let’s explore what sets them apart. The Core Difference: […]
CIRM’s $100M Plan to Revolutionize Rare Disease Treatment
For the 30 million Americans living with a rare disease, hope can feel distant. A staggering 95% of these conditions have no approved therapy, leaving patients and their families with few options. But what if we could change that? The California Institute for Regenerative Medicine (CIRM) has announced a groundbreaking $100 million plan to accelerate […]
Is the Future of Gene Editing Finally Here?
Developing new cell therapies is a long and difficult process. Scientists face many challenges, including the precision and safety of gene editing tools. What if there was a faster, more reliable way to bring these treatments to patients? REPROCELL’s latest announcement may have the answer. On January 28, 2026, REPROCELL launched StemEdit, a new clinical […]
Promising Phase 1 Results for Hemophilia A Gene Therapy
Expression Therapeutics announced promising Phase 1 clinical trial results for its novel gene therapy, ET3, treating hemophilia A. The trial, detailed in the New England Journal of Medicine, showed significant increases in Factor VIII levels and a reduction in bleeding events in participants with severe hemophilia A. The therapy uses a lentiviral vector targeting hematopoietic stem […]
CRISPR Therapeutics’ FDA Approval for CASGEVY™
CRISPR Therapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approving CASGEVY™ (exagamglogene autotemcel [exa-cel]), a groundbreaking CRISPR/Cas9 gene-edited cell therapy. This approval makes CASGEVY available for the treatment of transfusion-dependent beta thalassemia (TDT) in patients aged 12 and older. Approximately 1,000 patients in the U.S. are now eligible for […]
Stem Cell Transplant as a Curative Treatment for Sickle Cell Disease
Hosted by Expecting Health in collaboration with Be The Match, this webinar delved into the current practices and considerations surrounding bone marrow transplant as a potential curative treatment for Sickle Cell disease. The session aimed to shed light on the intricacies of the transplant process and to amplify awareness within the newborn screening community. Speakers: […]
Caring Cross Unveils Affordable Genetic Therapy Strategies
New press release announces the role of Caring Cross, a non-profit organization, in a newly published white paper from the Innovative Genomics Institute, titled “Making Genetic Therapies Affordable and Accessible.” The white paper is the result of yearlong research and focuses on strategies to increase the affordability and accessibility of genetic therapies, including CAR-T technology […]
RoslinCT and Lykan Bioscience: The Dynamic Duo Redefining the Future of Cell and Gene Therapy
RoslinCT and Lykan Bioscience, two leading Contract Development and Manufacturing Organizations (CDMOs) in the Cell and Gene Therapy industry, have announced their integration to form a unified business that will operate under the RoslinCT brand. This integration, facilitated by GHO Capital, a global investment firm, aims to establish a dominant player in the Advanced Cell […]
reNEW | Next generation stem cell research
reNEW is a unique global collaboration focusing on stem cell research involving three leading research institutions: the University of Copenhagen in Denmark, the Leiden University Medical Center in the Netherlands, and the Murdoch Children’s Research Institute in Australia. reNEW’s vision is to create a new generation of effective, safe, and socially sustainable stem cell-based therapies […]
Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts
San Diego, California and London, UK, October 17, 2022 – Replay, a genome writing company reprogramming biology by writing and delivering big DNA, today announced that it has established a scientific advisory board (SAB) comprising ten experts across a broad range of areas of scientific importance in genomic medicine and cell therapy. The newly formed SAB will provide input into […]